Roth Capital Comments on Accuray’s Q2 Earnings (NASDAQ:ARAY)

Accuray Incorporated (NASDAQ:ARAY) – Equities researchers at Roth Capital cut their Q2 2025 earnings per share estimates for Accuray in a research note issued to investors on Tuesday, November 19th. Roth Capital analyst J. Wittes now anticipates that the medical equipment provider will post earnings per share of $0.00 for the quarter, down from their previous estimate of $0.01. The consensus estimate for Accuray’s current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray’s Q4 2025 earnings at $0.05 EPS.

Separately, StockNews.com downgraded Accuray from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

Accuray Trading Up 2.1 %

NASDAQ:ARAY opened at $1.93 on Thursday. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. The firm has a fifty day simple moving average of $1.85 and a 200-day simple moving average of $1.83. Accuray has a 12 month low of $1.40 and a 12 month high of $3.05. The company has a market capitalization of $194.10 million, a P/E ratio of -11.21 and a beta of 1.40.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). The firm had revenue of $101.55 million during the quarter, compared to analysts’ expectations of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same period in the prior year, the business posted ($0.03) EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC purchased a new position in Accuray during the 2nd quarter worth approximately $910,000. Foundry Partners LLC grew its position in Accuray by 51.3% during the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock worth $3,937,000 after purchasing an additional 741,900 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Accuray by 9.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 73,146 shares of the medical equipment provider’s stock worth $181,000 after buying an additional 6,583 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Accuray during the second quarter worth about $132,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Accuray by 6,480.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 35,007 shares of the medical equipment provider’s stock worth $64,000 after buying an additional 34,475 shares during the last quarter. Institutional investors and hedge funds own 64.08% of the company’s stock.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.